Ignyta to Present at the 29th Annual Piper Jaffray Healthcare Conference Wed, 22 Nov 2017 12:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017, at 11:00 a.m.
Ignyta Reports Granting of Inducement Awards Thu, 16 Nov 2017 12:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that it has issued two inducement awards to new non-executive employees.
Ignyta to Present at the Jefferies 2017 London Healthcare Conference Thu, 09 Nov 2017 21:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Jefferies 2017 London Healthcare Conference on November 16, 2017, at 1:20 p.m.
Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer (SITC) Meeting Wed, 08 Nov 2017 13:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced new preclinical data for RXDX-106 – a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment through TYRO3, AXL, and MER receptor tyrosine kinase inhibition.
Ignyta reports 3Q loss Wed, 08 Nov 2017 00:51:53 +0000 On a per-share basis, the San Diego-based company said it had a loss of 51 cents. Ignyta shares have nearly tripled since the beginning of the year. In the final minutes of trading on Tuesday, shares hit ...
Ignyta to Present at Credit Suisse 26th Annual Healthcare Conference Wed, 01 Nov 2017 20:00:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at 11:35 a.m.
Ignyta Announces Pricing of Public Offering of Common Stock Fri, 20 Oct 2017 00:05:00 +0000 Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of 10.0 million shares of its common stock at a price to the public of $16.00 per share.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.